Every 424B that Cellectar Biosciences INC NEW (CLRB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CLRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLRB filings page.
Cellectar Biosciences is registering the resale by selling stockholders of up to 51,998,413 shares of its common stock pursuant to a May 4, 2026 private placement and related transactions.
The prospectus states the company will not receive proceeds from these resales, although it will receive proceeds from any cash exercise of Placement Agent Warrants, Pre-Funded Warrants or other Warrants; the resale registration satisfies contractual obligations under the Purchase Agreements.
Shares outstanding were 4,240,129 as of April 30, 2026 (adjusted to 5,858,182 to give effect to the RDO); the filing shows pro forma outstanding shares of 57,856,595 assuming full exercise of the registered instruments.
Cellectar Biosciences is offering 1,618,053 shares of Common Stock at $2.65 per share, generating aggregate gross proceeds of $4,287,840.45. Net proceeds to the company are estimated at approximately $3.9 million, which the company intends to use for working capital and to support plans to initiate a Phase 3 trial for iopofosine I 131.
The offering is concurrent with a private placement that includes up to 39,618,078 Common Warrant Shares, 2,116,887 Private Placement Shares and 9,471,086 Prefunded Warrants. The Common Warrants have an exercise price of $2.65 and become exercisable following the Stockholder Approval Date; Series A/B/C Warrants expire one, two and five years after that date, respectively. Shares outstanding after the offering are based on 4,240,129 shares as of April 30, 2026.
Cellectar Biosciences is registering up to 2,096,188 shares of common stock for resale by existing holders, all issuable upon exercise of previously issued Series I and Series II Inducement Warrants. These resale shares will be sold from time to time by the selling stockholders, and the company will not receive proceeds from their sales, only from any cash warrant exercises. Assuming full exercise of the Inducement Warrants, shares outstanding would be 6,336,322.
The October 2025 warrant inducement and related new warrants generated approximately $5.8 million in gross proceeds, and a July 2025 underwritten offering added about $6.9 million. As of September 30, 2025, estimated cash was about $12.6 million, which management believes can fund operations into the third quarter of 2026, while explicitly highlighting substantial doubt about continuing as a going concern without new capital or a strategic transaction.
Clinically, lead asset iopofosine I 131 for Waldenstrom macroglobulinemia has FDA Breakthrough Therapy designation and EMA scientific advice indicating a conditional marketing authorization filing "could be acceptable," potentially allowing commercial availability in EMA countries as early as 2027, subject to successful submissions and studies.